Given the regulatory approval and introduction of long-acting PrEP agents, there is a bright future for HIV prevention. Translating the science from innovative clinical trials into innovative regulatory approaches to these trials has the potential to lead to greater impact in the communities that could benefit most from long-acting PrEP. We will explore these new counterfactual trial approaches, and their implications for communities.